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Summary.-Groups of male and female beagle dogs were given daily doses of400 mg
of various mixtures of naphthylamines for up to 109 months. Survivors were killed
at 128 months. A variety ofpathological conditions was diagnosed, but the only effect
related to treatment was the induction of bladder neoplasms. All dogs which
received pure2-naphthylamine developed transitional-cell carcinomas ofthe bladder
within 34 months. Two of 8 dogs receiving 6% 2-naphthylamine in 1-naphthylamine
developed early carcinoma and 2/8 dogs receiving 0.5% 2-naphthylamine in
1-naphthylamine developed haemangioma ofthe bladder. Some ofthe dogs receiving
1-naphthylamine (total dose 950 g) and the controls had focal cystitis or hyperplasia,
but no neoplasia of the bladder.
These results confirm the carcinogenicity of 2-naphthylamine to dogs. No
carcinogenic effect of 1-naphthylamine was observed, indicating that it is at least
200 times less potent as a carcinogen than2-naphthylamine. The incidence ofbladder
cancer in dogs fed mixtures of both naphthylamines explains why previous experi-
mental and epidemiological studies of impure 1-naphthylamine have revealed
carcinogenicity.
NAPHTHYLAMINES have been manufac-
tured for many years as intermediates in
the production of dyes and antioxidants,
though in the United Kingdom the manu-
facture of 2-naphthylamine has been pro-
hibited and 1-naphthylamine controlled
by government regulation since 1967. The
association between the manufacture or
handling of 2-naphthylamine and the in-
duction of bladder cancer in man was
suspected from a number of case reports,
and the association was confirmed by the
careful epidemiological study ofCase et al.
(1954). An increased incidence of bladder
cancer in workers exposed to 2-naphthyl-
amine was also reported by Goldwater et
al. (1965) and Mancuso & El-Attar (1967).
Concomitantly with these epidemiological
studies, experiments have been carried out
to establish whether 2-naphthylamine is
carcinogenic in animals. Bladder cancer
was observed in dogs after the administra-
tion of commercial 2-naphthylamine
(Heuper et al., 1938; Bonser et al., 1956)
and purified 2-naphthylamine (Bonser,
1943; Conzelman & Moulton, 1972). Other
species susceptible to the induction of
bladder cancer by 2-naphthylamine in-
clude the rhesus monkey (Conzelman et
al., 1969) and hamster (Saffiotti et al.,
1967; Sellakamur et al., 1969) but not the
mouse (Hadidian et al., 1968). There is
confficting evidence on the susceptibility
of the rat (Hadidian et al., 1968; Bonser
et al., 1952; Hicks et al., 1978).
The data on the carcinogenicity of 1-
naphthylamine are not so clear. Com-
mercial 1-naphthylamine contained 3-6%
of 2-naphthylamine until the last decade,
when new production methods reduced
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levels dramatically. The presence of 2-
naphthylamine in commercial 1-naphthyl-
amine has made the interpretation ofmuch
of the epidemiology and experimental
workextremely difficult. Thus, the attribu-
tion of cases of bladder cancer in workers
exposed to 1-naphthylamine up to the late
1960s cannot be considered conclusive.
The work ofCase etal. (1954) distinguished
between workers exposed to 1-naphthyl-
amine alone and those engaged also in
working with 2-naphthylamine and benz-
idine. The 1-naphthylamine-exposedwork-
ers had an excess of bladder cancer, but
the 1-naphthylamine contained a signifi-
cant level of 2-naphthylamine. The pre-
sence of bladder papillomata in 2 dogs
administered commercial 1-naphthyl-
amine (Bonser et al., 1956) may be attri-
butable to contamination of 1-naphthyl-
amine by 2-naphthylamine. Other studies
in dogs (Gehrmann et al., 1949; Radomski
et al., 1980) andinhamsters (Saffiotti et al.,
1967; Sellakamur et al., 1969) failed to
demonstrate the induction of bladder
cancer by 1-naphthylamine.
The purpose of the study reported here
was to establish whether prolonged ad-
ministration of purified l-naphthylamine
or mixtures of 1- and 2-naphthylamine
similar in composition to early technical
1-naphthylamine could produce bladder
cancer in dogs.
METHODS AND MATERIALS
Animals and experimental design.-Beagle
dogs bred in our own facility were used.
Initially 18 males and 18 females, 9
months old, were included in the experiment.
After 75 months (June 1974) a further male
and female, 8 months old, were combined
with the surviving 2 males and 1 female from
the undosed control group to create a new
group (Group 6) to which 2-naphthylamine
was administered. The animals were dis-
tributed between 6 groups as in the Table in
the next column.
Accommodation.-Each dog was housed
in a single kennel and had daily access to an
exercise area. Each room contained 8 kennels
and housed one group for the duration of
dosing, except that in March 1975 the control
dogs were rehoused for a period of 17 days
Treatment
(Daily, 5 days
Group a week)
1 Control (lactose)
2 2 tablets (400 mg)
purified 1-naphthyla-
mine
3 2 tablets (400 mg)
1-naphthylamine
containing 0.5%
2-naphthylamine
4 2 tablets (400 mg)
1-naphthylamine
containing 6%
2-naphthylamine
5 Undosed control
6 2 tablets (400 mg)
pure 2-naphthyla-
mine
Dogs
M F Origin
4 4 Initial
group
4 4 Initial
group
4 4 Initial
group
4 4 Initial
group
2 2 Initial
group
2 1 Group 5
+ +
I 1 Additional
dogs
in the rooms housing other groups. Cleaning
and feeding equipment was confined to indi-
vidual rooms and gloves, boots and aprons
were worn by all staff on entering the rooms.
The dogs were rehoused after dosing had
ceased.
Diet.-All dogs received commercial dog
diets, but one dog with signs of chronic
nephritis was kept on a low-protein diet
from the 75th month to the end ofthe experi-
ment.
Preparationanddosing ofnaphthylamines.-
Purified 1-naphthylamine (containing less
than 100pt/106 2-naphthylamine) and pure
2-naphthylamine were supplied by Imperial
Chemical Industries Limited, Organics Divi-
sion, Blackley, Manchester, U.K. The two
compounds were mixed in the appropriate
proportions and tablets prepared from the
following formulation:
Naphthylamine or lactose
Spray-dried lactose
Microcrystalline cellulose
Magnesium stearate BP
Whole tablet
mg
200
274
120
6
600
Tablets were stored in a ventilated cabinet
and dispensed into gelatin capsules for dosing.
One gelatin capsule, containing 2 tablets of
the appropriate formulation, was dosed
orally to each dog in Groups 1, 2, 3, 4 and 6,
daily for 5 days a week.
Groups 1, 2, 3 and 4 were started in March
1968 and dosing continued for 109 months,
the experiment terminating in November
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1978 after 128 months. Group 6 was consti-
tuted in June 1974 and dosing continued
with 2-naphthylamine for 34 months. No
dogs from Group 6 survived longer than 47
months from the start ofdosing.
Bioavailability of naphthylamines.-Infor-
mation on the dissolution of the naphthyla-
mine tablets was obtained by estimating
disintegration times in simulated gastric
fluid (pH 1.5) in the standard B.P. test.
Five or 6 tablets from 2 batches of each type
were used.
Observations.-The dogs were observed
daily, and any dogs with clinical symptoms
requiring treatment were treated under
veterinary supervision. In principle, treat-
ment was aimed at prolonging the life of the
dogs or alleviating painful conditions, but it
was confined to treatment unlikely to affect
the purpose and integrity ofthe study. Thus,
treatment of wounds from fighting or the
removal of dental tartar required general
anaesthesia, and antibiotics were used to
control various infections. Superficial tumours
were removed surgically and examined
histopathologically.
Dogs were weighed weekly for the first 13
weeks and thereafter at 4-weekly intervals.
Blood samples were taken for clinical chem-
istry andhaematology at 6-monthlyintervals.
The following parameters were estimated:
haemoglobin, red-cell count and total and
differential white-cell count, erythrocyte
sedimentation rate, prothrombin time,
kaolin-cephalin-time, methaemoglobin, plas-
ma alkaline phosphatase (ALP), alanine
transaminase (ALT) and ornithine carboxyl
transferase (OCT) activities, plasma sodium
and potassium, blood glucose and urea. Dur-
ing the 5th and 6th years of the experiment
urine samples were collected by catheter for
cytology.
Pathology.-Dogs which were moribund,
and those that survived to the end of the
experiment were killed with i.v. pentobar-
bitone and exsanguinated. All dogs were
subjected to a full postmortem examination
and tissues from up to 30 organs, and any
organs with gross abnormalities, were taken
for histopathology. After fixation in buffered
formalin, tissues for histopathology were
embedded in wax and 5,um sections prepared.
Sections were stained with haematoxylin
and eosin for microscopy. Additional special
stains were used on selected sections to aid
diagnosis.
RESULTS
Naphthylamine dosage
The sample of 1-naphthylamine used
for the experiment contained 5 pt/106 of
2-naphthylamine (nominal value, less than
100 pt/106). The sample of 2-naphthyl-
amine contained no significant levels of
impurities.
The average daily doses administered to
the various groups are given in Table I.
Each dog dosed at 400 mg per day for 109
months received 945 g of naphthylamine.
The 4 dogs in Group 6, dosed for 34
months, received 290 g of 2-naphthyl-
amine, Dog 35 from Group 6 died after 27
months and received 230 g. As the
weight of the dogs changed with time, the
group mean daily dose varied, but was
usually within 3 mg/kg/day of the mean
value calculated for the whole experiment.
Disintegration times of all tablets were
in the range of 21-16 min except for one
batch of 1-naphthylamine tablets where
the range was 25-30 min.
Haematology
Some individual values were abnormal,
but there was no dose-related trend in any
of the parameters measured. Dogs with
haematuria showed moderate to marked
anaemia.
Clinical chemistry
There were no consistent trends in the
control groups. Group 2 (l-naphthylamine)
dogs had transient increases in plasma
ALP, ALT and OCT activities, female 16
having marked increases from 7 years.
Groups 3 and 4 had more frequent tran-
sient increases in plasma enzymes. Four of
the 5 dogs in Group 6 had high plasma
ALT activities, with less effect on plasma
OCT. Plasma ALP activities were normal,
while blood urea levels rose later in the
study. No effects were observed on blood
glucose or plasma K and Na.
Clinical observations
A variety of conditions was observed in
the dogs, including fits in some dogs and
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TABLE I.-Group mean daily doses ofnaphthylamines
Group
1
Compound(s)
2 1-naphthylamine
3 1-naphthylamine + 0.5%
2-naphthylamine
4 1-naphthylamine+ 6%
2-naphthylamine
6 2-naphthylamine
Sex
M
F
M
F
M
F
M
F
Mean daily
dose
(mg/kg)*
0
18-4
22-0
18-5
21-1
18-6
20-9
18-4
21*3
Approximate
mean daily
dose of
2-naphthylamine
(mg/kg)
0
9 x 10-5t
1-1 x 10-5t
009
0*11
1.1
1-25
18-4
21-3
Total dose of
2-naphthylamine
(g)
0
4*75 x 10-6t
4.75
56-7
290
* Calculated as the mean daily dose administered 5 days per week to the 4 groups dosed naphthylamines:
1 109 400
t=o xt
where x=mean daily dose,
xt= group mean weight at time t,
T =number oftimes dosed (in this case, 5 days per week).
t Based on 5 pt/106 of2-naphthylamine in the purified l-naphthylamine.
various conditions attributed to ageing.
All dogs in Group 6, 1 in Group 4 and 1 in
Group 2 suffered from haematuria for
variable periods before they died or were
killed in a moribund condition. In each
case lesions of the bladder were observed
at necropsy. No other treatment-related
effects were found. The average body
weights of treated male and female dogs
were 15-3 and 13-5 kg respectively. No
treatment-related effect on body weight
was found.
Urinary cytology
An attempt to identify dogs with early
bladder lesions by means of urinary
cytology was unsuccessful. Similar prob-
lems had previously been reported
(Radomski et al., 1971).
Pathology ofthe bladder
The only organ to show gross lesions
considered to be related to treatment was
the urinary bladder. All 5 dogs in Group 6
(given 2-naphthylamine) had large cauli-
flower-like masses involving most of the
bladder mucosa and nearly filling the
lumen. Two dogs in Group 4 each had
solitary papilliform masses protruding
from the mucosa, the largest being 2 x 2 x
05 cm. Two dogs in Group 3 had a solitary
2mm diameter red nodule on the mucosal
surface. One dog in Group 2 had a large
blood clot in the bladder and the mucosa
showed localized reddening.
The most significant histopathological
finding was the transitional-cell carcin-
omas ofthe bladder in all 5 dogs receiving
2-naphthylamine (Fig. 1) and 2 early
carcinomas in the 8 dogs receiving a mix-
ture of 1-naphthylamine and 6% 2-
naphthylamine. Two of the 8 dogs re-
ceiving 1-naphthylamine+0.5% 2-naph-
thylamine had solitary haemangiomas
arising in the submucosa and protruding
into the bladder lumen. The 5 dogs in
Group 6 developedbladdertumours within
25 to 47 months of dosing, whereas the
bladder tumours in Groups 3 and 4 were
detected at, or near to, the end of the
study at 128 months.
One of the 8 dogs receiving purified
1-naphthylamine, which had shown
haematuria during life, had focal cystitis
with dilation of the submucosal blood
vessels (Fig. 2) and associated localized
haemorrhage. Focal epithelial hyperplasia
of the wall of the bladder was seen in 2
dogs in the control group and 1 in Group 4.
In addition to the bladder lesions, hyper-
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Group 1 (Lactose)
TABLE II.-Summary of
2 (1-naphthylamine)
Number ofdog 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Sex ofdog M F M F
Time to death (months)
from start ofdosing 24 128 95 125 122 128 84 128 120 128 127 54 18 100 126 109
Histopathological diagnosis
Bladder Haemangioma
Early carcinoma
Transitional-cell carcinoma
Aorta Chemodectoma
Gut Leiomyoma x
Lymphosarcoma x
Adrenal Cortical adenoma x
Gall bladder Submucosal fibroma x
Liver Cholangiocarcinoma
Pancreas Acinar adenoma x
Pituitary Basophil adenoma x
Thyroid Follicular adenoma x x
Parafollicular adenoma
Carcinoma x x
Parathyroid Adenoma
Spleen Fibrosarcoma x
Eye Melanoma ofiris
Skin Lipoma x x x
1iaemangioma x 1
Papilloma x
Keratoacanthoma x x12
Histocytoma
Haemangio-pericytoma
Apocrine carcinoma x
Squamous carcinoma
Mast-cell tumour
Nasal cavity Fibrosarcoma
Oral cavity Epulis x
Ovary Granulosa-cell tumour
Adenoma x
Vagina Fibroma
Mammary Mixed malignant tumour x 9 10
gland Duct carcinoma
Testis Seminoma
Sertoli-cell tumour (bilateral)
Reference numbers within the table
1 103 months
2 113 months
3 106 months
4 97 months
5 100 months
6 124 and 126 months
7 109 months
8 115 months
9 4 tumours: 106, 109, 115 months
and at termination (128 months)
plasia of the epithelium of the ureter was
seen in single dogs in Groups 3 and 4 and
3 dogs in Group 6.
Pathology ofother organs
A variety of gross lesions was observed
at postmortem examination ofthe dogs in
all groups. Histopathological examination
revealed a range of conditions, many of
which (e.g. interstitial nephritis, nodular
hyperplasia of the spleen and liver,
hepatic granulomata and inflammatory
changes in the respiratory tract) are
recognized as common in ageing dogs. In
none except for those of the urinary tract
was there a marked difference in incidence
from the control group, and they were not
considered to be caused by treatment with
naphthylamines.
Organ
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tumour incidence
3 (1-naphthylamine +
05% 2-naphthylamine)
A
17 18 19 20 21 22 23 24
M\ F
M F
4 (1-naphthylamine+ 6 5
6% 2-naphthylamine) (2-naphthylamine) Control
t~~ ~ ~~~ A r- A
'
25 26 27 28 29 30 31 32 33 34 35 37 38 36
_ A
A AI
M F M M F M F F
_ _ __AV X V k
A
17 128 121 128 122 68 128 108 124 128 66 125 128 128 125 96 44 38 27 47 35
x x
x x
x x x x x
x
x x
x
x x x
x
x x x x
x
x x x
x
x x x
x x x xx
x
x x3
X 8
x6 X 7
X 2
x~~~~~~~~
x~~~~~~~~~~
x~~~~~~~~~~
x x~~~~~~~~~~~ xx~~~~~~~
X~~~~~~~~
10 82 months
11 119 months and at termination (128 months) 12 88 months
Benign or malignant tumours were
diagnosed in 29 dogs (Table II). Twelve
tumours were removed surgically during
the course ofthe experiment from 10 dogs.
Nine of these were from the skin or sub-
cutis, 2 from the mammary gland and 1
from the testis. The diagnosis of each
tumour is given in Table II.
The number of tumour-bearing animals
for each group is given in Table III. The
only statistically significant differences in
incidence were the increased incidence of
bladder tumours (P < 0 01) and of malig-
nant-tumour-bearing animals (P < 0-05) in
Group 6 (2-naphthylamine) over the con-
trols. There was no significant difference
between tumour incidence in Groups 2, 3
and 4 and controls.
28
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FIG. 1.-Transitional-cell carcinoma of the bladder in a dog which had received 2-naphthylamine for
47 months, showing extensive invasion of the muscle of the bladder wall. H. & E. x 270.
F'IG. 2.-Bladder of a dog which had received purified 1-naphthylamine for 109 months. There are
several large dilated blood vessels in the submucosa and moderate inflammatory-cell infiltration.
H.& E. x 105.
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DISCUSSION
Unlike many of the previous studies on
the carcinogenicity ofnaphthylamines, the
purity of the chemicals administered in
this study was high. The contamination of
1-naphthylamine by 2-naphthylamine (5
pt/106) meant extremely small doses of
2-naphthylamine to the dogs in Group 2.
TABLE III.-Number of tumour-bearing
animals and tumours in each group
Group 1 2 3 4 6
No. ofanimals*
No. ofmalignant TBA
No. ofbenign TBA
Total TBA
Total malignant tumours
Total benign tumours
Total tumours/group
7
2
3
5
2
8
10
7 7
4 4
2 2
6 6
6 4
8 13
12 17
8
5
1
6
8
14
22
5
5
0
5
7
0
7
* No. of animals surviving longer than 50 months,
except for Group 6, where there were no survivors
after 47 months.
TBA =Tumour-bearing animals.
The time taken for the naphthylamine
tablets to disintegrate was within the
specified maximum disintegration times
for uncoated tablets, except for one batch
ofthe 1-naphthylamine tablets. The effect
of this slow disintegration time on bio-
availability is difficult to assess accurately,
but assuming that the batches examined
were representative ofall batches made, it
is likely to have delayed absorption with-
out affecting the total amount absorbed.
Transient increases in plasma enzyme
levels, which were most marked in dogs on
pure 2-naphthylamine, may have been
associated with naphthylamine treatment,
though no statistical treatment of the
results is possible. The marked increases
in plasma ALT activity were not asso-
ciated with pathological changes in the
liver, and their cause is unexplained. High
blood urea levels are to be expected in
dogs with cancer of the urinary tract.
The induction of malignant tumours of
the bladder in the 5 dogs receiving 2-
naphthylamine confirms the carcino-
genicity of this compound. Similarly, the
induction of a low incidence of bladder
cancer in the group receiving 1-naphthyl-
amine with 6% added 2-naphthylamine
provides an explanation for the carcino-
genic effect of impure l-naphthylamine
in early carcinogenicity and epidemiology
studies. The significance of haemangiomas
of the bladder in 2 of the dogs receiving
l-naphthylamine +0-5% 2-naphthylamine
is uncertain, as similar lesions do not
appear to have been reported in previous
studies with naphthylamines in the dog.
According to Moulton (1978), haemangi-
oma and haemangiosarcoma account for
6% of all naturally occurring bladder
neoplasms in domestic animals.
The absence of bladder cancer in the
dogs receiving 1-naphthylamine is evi-
dence of its non-carcinogenicity. Previous
studies (Gehrmann et al., 1949; Radomski
et al., 1980) which were limited, for ex-
ample by the absence of control groups,
were also negative. In this study large
doses were given over a prolonged period
of time and both negative and positive
controls were used. Although the number
of animals was relatively small (8 per
group) from a statistical point ofview, our
study is the largest study reported on
amine carcinogenesis in dogs, and was
initiated at a time when group sizes, even
in rodent studies, were relatively small.
Thus in spite ofthe inadequacies resulting
from small group sizes, this experiment
provides the best data so far available on
1-naphthylamine carcinogenesis in dogs.
One dog in the group receiving 1-
naphthylamine developed haematuria.
The localized vascular dilation observed
in the bladder submucosa may represent a
pre-angiomatous change, but cannot be
considered neoplastic. No similar lesion
was observed in the other groups receiving
naphthylamine, so it is unlikely to be
treatment-related.
An experiment ofthis size,withalimited
number of animals in each group, may be
considered inadequate to define the non-
carcinogenicity of 1-naphthylamine. In-
deed, proof of non-carcinogenicity is
always impossible, but a comparison ofthe
doses of naphthylamines administered
gives an indication ofthe minimum differ-
899900 I. F. H. PURCHASE ET AL.
ence in potency between the 2 compounds.
If the 2 haemangiomas of the bladder in
Group 3 are taken as an indication of the
activity of2-naphthylamine, the minimum
dose of 2-naphthylamine to produce an
effect is about 0-1 mg/kg/day (Table I).
This is 0.5% of the dose of 1-naphthyl-
amine givento Group 2; hence l-naphthyl-
amine can be considered to be at least
200 x less potent than 2-naphthylamine in
inducing bladder cancer in dogs. If the
much shorter latent period in the group
receiving pure 2-naphthylamine is taken
into account, the potency difference can
be considered to be even greater.
A large variety of other tumours was
seen in this experiment. Larger numbers
of tumours of the thyroid and skin were
observed in the naphthylamine-treated
groups (2, 3 and 4) than in the control
group, but the difference was not signifi-
cant.
The carcinogenicity of 2-naphthylamine
is attributed to its metabolism in the liver
to the N-hydroxy and -nitroso derivatives,
which are excreted in the urine either as
conjugates or as the metabolite itself. The
conjugates are unstable in the acidic con-
dition in the bladder, and hydrolyse
yielding the original oxidation products
(Radomski et al., 1971).
In the case of both 1- and 2-naphthyl-
amine the N-hydroxy derivatives are
carcinogenic. It is thus not surprising that
both 1- and 2-naphthylamine are positive
in in vitro mutagenicity assays which in-
corporate liver microsomal preparations
for metabolism (de Serres & Ashby, 1981).
The N-hydroxy derivative of 1-naphthyl-
amine is excreted in the urine (Deichmann
& Radomski, 1969), is considered stable
and unreactive with low-mol.-wt urinary
nucleophils (Kadlubar et al., 1978) and is
more potent at sites of direct application
than the 2-hydroxy derivative (Radomski
et al., 1971; Kadlubar et al., 1978).
The reason for the absence of a carcino-
genic effect of 1-naphthylamine may,
however, relate to the quantity of active
metabolites excreted in the urine. There
is a quantitative correlation between the
carcinogenicity ofthese compounds to dog
bladder and the combined excretion of
N-hydroxy and N-nitroso metabolites
(Clayson & Garner, 1976). However, there
is only about a 40-fold difference in the
quantity of metabolites excreted after a
dose of 5 mg/kg (0.8 ,ug for 1-naphthyl-
amine and 30 jig for 2-naphthylamine
(Radomski et al., 1971)) and at the higher
doses used in our experiment this differ-
ence may even be smaller. This quanti-
tative difference in the metabolism of 1-
and 2-naphthylamine is reflected in a
similar difference in the level of reaction
with DNA in the urothelium. DNA-
naphthylamine adducts could be detected
in the urothelium (18.5 adducts/108
nucleotides) 2 days after administration
of 2-naphthylamine to a dog; but none
were detected after administration of 1-
naphthylamine (Kadlubar et al., 1981).
Because the limit of detection of adducts
was 1/108 nucleotides, the magnitude of
the difference can only be expressed as at
least 18-fold. More precision in the estima-
tion ofthe DNA adducts could provide an
estimate of the difference in potency
between the naphthylamine isomers. Com-
parison with in vivo data and the levels of
excretion of metabolic products would be
a further step in understanding the reason
for the absence of carcinogenic effect of
1-naphthylamine.
Manypeople have contributed to this study during
the last 11 years, and the continued interest and
support of ICI Organics Division in this project was
crucial to its successful outcome. Thanks are due to
Dr D. C. Taylor for determining disintegration times,
and to Mrs I. Stevenson for skilled technical
assistance.
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